10:48 PM EST, 11/11/2026 (MT Newswires) -- Incyte Biosciences secured approval from the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, for Zynyz to treat patients with squamous cell carcinoma of the anal canal. The MHRA issued the latest approval on Nov. 5, according to a Wednesday release. Zynyz, or retifanlimab, is already authorized in the UK for treating advanced Merkel cell carcinoma, a rare form of skin cancer. The UK regulator said a study involving 308 people demonstrated that retifanlimab combined with chemotherapy was more effective and increased the lifespan of patients with the advanced anal cancer without their condition getting worse, compared with placebo plus chemotherapy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.